- Simtra BioPharma Solutions has acquired a 65-acre site with over 300,000 sq ft of expansion space near its Bloomington, Indiana, facility.
- The company is evaluating plans to install its first U.S. commercial-scale oncology injectable manufacturing lines at the site.
Simtra BioPharma Solutions, a global CDMO focused on injectable medicines, has announced the acquisition of a 65-acre property in Bloomington, Indiana, from Cook Group. The site, located at 301 N. Curry Pike, offers more than 300,000 square feet of available under-roof space, adjacent to Simtra’s existing manufacturing operations.
The move supports Simtra’s plans to expand its contract manufacturing capabilities in North America, with the company citing increased demand from both new and existing customers. The facility will allow Simtra to scale its operations more rapidly, particularly for next-generation oncology treatments, including antibody-drug conjugates (ADCs).
“This purchase gives us the foundation to grow with purpose, building the advanced injectable capacity our customers need while strengthening our presence in North America,” said Franco Negron, Chief Executive Officer of Simtra BioPharma Solutions.
Simtra is currently assessing the installation of isolator-based vial and prefilled syringe filling lines at the new location, marking its first U.S.-based commercial-scale production for oncology-focused injectables. The company’s “build-to-suit” model will be used to tailor manufacturing lines to specific customer and product needs.
The acquisition aligns with Simtra’s broader investment strategy, which includes a $250 million expansion project underway at its existing Bloomington site, alongside recent investments in Germany such as a $100+ million production building and a $14 million conjugation and purification suite in Halle/Westfalen. Simtra noted that it will work with Monroe County officials on a phased development plan for the newly acquired site.